Filing Flows › GeneDx Holdings (WGS) › Guidance history
GeneDx Holdings (WGS) guidance history: what it guided and what it reported
GeneDx Holdings gave guidance in 12 earnings releases on file since Apr 29, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +16.9% against the guided midpoint. Its releases raised guidance 9 times and lowered it 0 times.
Revenue
Met or beat 2 of 2 periods (2 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $540M–$555M (Jan 12, 2026) → reaffirmed $540M–$555M (Feb 23, 2026) → lowered $475M–$490M (May 4, 2026) → reaffirmed $475M–$490M (Aug 3, 2026) → reaffirmed $475M–$490M (Nov 9, 2026) | — | to be reported | — |
| FY2025 | $350M–$360M (Feb 18, 2025) → raised $360M–$375M (Apr 30, 2025) | $428M | above the range | +16.3% |
| FY2024 | $235M–$245M (Apr 29, 2024) → raised $255M–$265M (Jul 30, 2024) | $305M | above the range | +17.5% |
Adjusted gross margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q2 2026 | 70.0% (May 4, 2026) | — | — | — |
| FY2026 | 70.0% (Jan 12, 2026) → raised 71.0% (Feb 23, 2026) | — | to be reported | — |
| FY2025 | 70.0% (Feb 18, 2025) → lowered 66.0%–68.0% (Apr 30, 2025) | — | — | — |
| FY2024 | 61.0% (Apr 29, 2024) → lowered 60.0% (Jul 30, 2024) → raised 62.0% (Oct 29, 2024) | — | — | — |
Net income
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.0M (Feb 23, 2026) | — | to be reported | — |
| FY2025 | $750K (Feb 18, 2025) | — | — | — |
The latest quarter
GeneDx Holdings, Q3 2026: revenue $123M (+5% year over year), operating margin -8.5%, net loss $12.3M, operating cash flow −$10.6M. The chart follows the revenue to costs, profit and cash.
Questions
Does GeneDx Holdings beat its guidance?
GeneDx Holdings gave guidance in 12 earnings releases on file since Apr 29, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +16.9% against the guided midpoint.
How often does GeneDx Holdings raise guidance?
Its earnings releases raised guidance 9 times and lowered it 0 times since Apr 29, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.